RSNA 2004

Nov 28, 2004

Show attendees and exhibitors take a break for lunch on the second day of RSNA 2004.

none

Fapi Rgd Thumbnail

SNMMI: Dual-targeting radioligand therapy safe for several cancers

June 22, 2025

Join Us June 26 at 12 Noon ET for a FREE webinar!

Join Us June 26 at 12 Noon ET for a FREE webinar!

June 12, 2025

Pa eymt6 J Xb Ss Thumbnail

SNMMI: Dual PET/MRI technique could help manage primary aldosteronism

June 22, 2025

Gokce Bilgin, MD, presented results of a Pluvicto study June 21 at SNMMI 2025 in New Orleans.

SNMMI: Retreatment with Lu-177 PSMA-617 shows promise in mCRPC patients

June 21, 2025

SNMMI: Dual-targeting radioligand therapy safe for several cancers

A new "dual-targeting" radioligand therapy has been shown to be safe and effective in humans.

June 22, 2025

Fapi Rgd Thumbnail

Video from SNMMI: Phillip Kuo on new Alzheimer’s disease imaging guidelines

A video interview with Phillip Kuo, MD, PhD, on Alzheimer's disease imaging.

June 22, 2025

Screenshot (2455)

SNMMI: Dual PET/MRI technique could help manage primary aldosteronism

Using two imaging agents with PET/MRI could help manage patients with primary aldosteronism.

June 22, 2025

Pa eymt6 J Xb Ss Thumbnail

SNMMI: Retreatment with Lu-177 PSMA-617 shows promise in mCRPC patients

Retreatment with Lu-177 PSMA-617 is emerging as a potential approach in men with prostate cancer.

June 21, 2025

Gokce Bilgin, MD, presented results of a Pluvicto study June 21 at SNMMI 2025 in New Orleans.

SNMMI: New PET tracers developed for imaging brain disorders

Two newly developed PET imaging agents are effective for identifying a highly expressed receptor in neurological and psychiatric conditions.

June 21, 2025

New H3 Tracers Thumbnail

SNMMI: SPECT/CT valuable after Lu-177 therapy

Post-therapy SPECT/CT imaging can optimize treatment outcomes and protected patients undergoing radiopharmaceutical therapy.

June 21, 2025

Top image displays a patient assessed for acute renal failure following third Lutathera administration where 3D dosimetry showed an average-per-administration kidney absorbed dose of 5 Gray, with total course of therapy being well under toxicity limits. Bottom image displays a patient’s absorbed dose to the colon after his first dose of Pluvicto where 3D dosimetry was used to confirm transient bowel obstruction leading to treatment management.

DL model improves detection of breast arterial calcifications

By Amerigo Allegretto

Researchers have developed a deep-learning (DL) model that can find and characterize breast arterial calcifications on mammograms.

June 20, 2025

2025 06 20 Academicrad Bacs Deep Learning Thumbnail

Brain MRI helps predict outcomes in cardiac arrest survivors

By Kate Madden Yee

Quantitative brain MRI data appear to help clinicians forecast the effects of out-of-hospital cardiac arrest among those who survive it.

June 20, 2025

Could radiation therapy for breast cancer lower Alzheimer's risk?

By Amerigo Allegretto

Radiation therapy for breast cancer treatment may lead to a lower risk of developing Alzheimer's disease in survivors.

June 20, 2025

Woman Anxious Thumbnail

Removing patient fees for DBT improves utilization, but inequity remains

By Erik L. Ridley

In a recent study, eliminating out-of-pocket costs for DBT reduced, but did not eliminate, disparities in utilization.

June 19, 2025

Medical Bill Final Notice

PET/CT metric improves staging of patients with lung cancer

A group in Korea suggests adding maximum standardized uptake values into initial lung cancer staging guidelines.

June 19, 2025

3 ways to manage effects of medical malpractice stress syndrome

By Kate Madden Yee

Medical malpractice stress syndrome can cause significant emotional, behavioral, and physical symptoms.

June 19, 2025

Doctor Technologist Burnout

Page 1 of 147